Xia Baomei, Zhang Hailou, Xue Wenda, Tao Weiwei, Chen Chang, Wu Ruyan, Ren Li, Tang Juanjuan, Wu Haoxin, Cai Baochang, Doronc Ravid, Chen Gang
Center for Translational Systems Biology and Neuroscience, School of Basic Biomedical Science, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
Key Laboratory of Integrative Medicine for Brain Diseases, School of Basic Biomedical Science, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
Cell Mol Neurobiol. 2016 Oct;36(7):1189-96. doi: 10.1007/s10571-015-0316-1. Epub 2016 Jan 29.
Accumulating evidence indicated that N-methyl-D-aspartate (NMDA) receptors are involved in the pathophysiology of depression and implicated in therapeutic targets. NMDA antagonists, such as ketamine, displayed fast-onset and long-lasting antidepressant activity in preclinical and clinical studies. Previous studies showed that Yueju pill exerts antidepressant effects similar to ketamine. Here, we focused on investigating the association of acute and lasting antidepressant responses of Yueju with time course changes of NMDA receptor subunits NR1, NR2A, and NR2B expressions in the hippocampus, a key region regulating depression response. As a result, Yueju reduced immobility time in the forced swimming test from 30 min to 5 days post a single administration. Yueju acutely decreased NR1 and NR2B protein expression in the hippocampus, with NR2A expression unaltered. NR1 expression remained down-regulated 5 days post Yueju administration, whereas NR2B returned to normal level in 24 h. Yueju and ketamine similarly ameliorated the depression-like symptoms at least for 72 h in learned helplessness test. They both reversed the up-regulated expression of NR1 in the learned helpless mice 1 or 3 days post administration. Different from ketamine, the antidepressant effects of Yueju were not influenced by blockade of amino-3-hydroxy-5-methyl-4-isoxazole propionate receptor. These findings served as preclinical evidence that Yueju may confer acute and long-lasting antidepressant effects by favorably modulating NMDA function in the hippocampus.
越来越多的证据表明,N-甲基-D-天冬氨酸(NMDA)受体参与抑郁症的病理生理过程,并与治疗靶点相关。NMDA拮抗剂,如氯胺酮,在临床前和临床研究中显示出快速起效和持久的抗抑郁活性。先前的研究表明,越鞠丸具有与氯胺酮相似的抗抑郁作用。在此,我们重点研究越鞠丸急性和持久抗抑郁反应与海马体中NMDA受体亚基NR1、NR2A和NR2B表达随时间变化的关系,海马体是调节抑郁反应的关键区域。结果显示,单次给药后30分钟至5天,越鞠丸可减少强迫游泳试验中的不动时间。越鞠丸可急性降低海马体中NR1和NR2B蛋白表达,而NR2A表达未改变。越鞠丸给药5天后,NR1表达仍下调,而NR2B在24小时内恢复至正常水平。在习得性无助试验中,越鞠丸和氯胺酮至少在72小时内同样改善了抑郁样症状。它们在给药后1天或3天均逆转了习得性无助小鼠中NR1上调的表达。与氯胺酮不同,越鞠丸的抗抑郁作用不受α-氨基-3-羟基-5-甲基-4-异恶唑丙酸受体阻断的影响。这些发现作为临床前证据表明,越鞠丸可能通过有利地调节海马体中的NMDA功能而产生急性和持久的抗抑郁作用。